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Background: Chymotrypsin C (CTRC) targets specific regulatory cleavage sites within trypsinogens and
procarboxypeptidases.
Results: The crystal structure of CTRC reveals the structural basis of substrate specificity.
Conclusion: Long-range electrostatic and hydrophobic complementarity drives CTRC association with preferred substrates.
Significance: The observations reveal the mechanistic basis for CTRC selectivity in digestive enzyme activation and
degradation.
Human chymotrypsin C (CTRC) is a pancreatic serine prote-
ase that regulates activation and degradation of trypsinogens
and procarboxypeptidases by targeting specific cleavage sites
within their zymogen precursors. In cleaving these regulatory
sites, which are characterized by multiple flanking acidic resi-
dues, CTRC shows substrate specificity that is distinct from that
of other isoforms of chymotrypsin and elastase. Here, we report
the first crystal structure of active CTRC, determined at 1.9-A˚
resolution, revealing the structural basis for binding specificity.
The structure shows human CTRC bound to the small protein
protease inhibitor eglin c, which binds in a substrate-like man-
ner filling the S6-S5 subsites of the substrate binding cleft. Sig-
nificant binding affinity derives from burial of preferred hydro-
phobic residues at the P1, P4, and P2 positions of CTRC,
although acidic P2 residues can also be accommodated by for-
mation of an interfacial salt bridge. Acidic residues may also be
specifically accommodated in the P6 position. The most unique
structural feature of CTRC is a ring of intense positive electro-
static surface potential surrounding the primarily hydrophobic
substrate binding site. Our results indicate that long-range elec-
trostatic attraction toward substrates of concentrated negative
charge governs substrate discrimination, which explains CTRC
selectivity in regulating active digestive enzyme levels.
Digestive proteases are synthesized and secreted by the pan-
creas as inactive zymogens. Physiological activation takes place
in the duodenum, where enteropeptidase initiates an activation
cascade by specifically activating trypsinogens, which in turn
activate chymotrypsinogens, proelastases, procarboxypepti-
dases, and other digestive enzymes (1). Premature activation of
trypsin within the pancreas is understood to be a major initiat-
ing factor in chronic pancreatitis, and chymotrypsinC (CTRC)4
is a significant player in this process. In approximately half of
the families affected by autosomal dominant hereditary pancre-
atitis, the disease is caused bymutations in the cationic trypsin-
ogen gene PRSS1 that result in either enhanced trypsinogen
activation or resistance to degradation (2–4). CTRC possesses
the unique capacity to impact trypsinogen activation and sta-
bility via two opposingmechanisms: it can cleave cationic tryp-
sinogen either at Phe18-Asp19 within the trypsinogen activation
peptide, leading to enhanced autoactivation (5), or at Leu81-
Glu82 within the Ca2-binding loop, resulting in degradation
(6). A number of disease-causing cationic trypsinogen muta-
tions exert their effect in part through accelerating cleavage
by CTRC at Phe18-Asp19 or through diminishing cleavage by
CTRC at Leu81-Glu82 (4). The p.A16V mutation, which
accounts for a small percentage of hereditary pancreatitis kin-
dreds and is also associatedwith idiopathic chronic pancreatitis
(7, 8), appears to exert its pathological effect solely by increasing
the vulnerability of the cationic trypsinogen activation peptide
to cleavage byCTRC (4). Finally, severalmutations in theCTRC
gene itself that lead to loss or impairment of protein function
are significantly associated with chronic pancreatitis (9–12).
Both cationic trypsin and CTRC are members of the chymo-
trypsin family of serine peptidases, which share a common two
-barrel-fold, a famous triad of catalytic residues Ser, His, and
Asp, and a conserved catalytic mechanism for nucleophilic
cleavage of peptide bonds. Although these enzymes all catalyze
the same reaction, they are differentiated by the distinct sub-
strate sequences that they recognize through a series of subsites
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located within the active site cleft between the two -barrels
(13, 14). CTRC has 50–66% sequence identity with human
pancreatic elastase isoforms, which have broad specificity for
cleavage after hydrophobic P1 residues,5 and 40% sequence
identity with other human chymotrypsin isoforms, which typ-
ically cleave after aromatic P1 residues. CTRC distinguishes
itself from these other family members by uniquely targeting
the regulatory cleavage sites involved in trypsinogen activation
(5) and degradation (6), and also serves as a co-activator, with
trypsin, of procarboxypeptidases CPA1 and CPA2 (15). The
inability of other chymotrypsin and elastase isoforms to target
these regulatory sequences (5, 15, 16) points to the existence of
unique elements of CTRC specificity, as does a recent study in
which we have identified selective inhibitors of CTRC using
phage display (17).
The mechanisms by which CTRC, confronted with multiple
potential substrates and cleavage sites, selects from among
them, is critical to understanding its protective role in the pan-
creas and its pathological role in disease. Given the opposing
effects of trypsinogen cleavage by CTRC within the activation
peptide versus the Ca2-binding loop, it is apparent that the
hierarchy of CTRC selectivity toward these competing sites has
been carefully titrated by nature. Remarkably, even a very subtle
mutation within a cleavage site can shift the activity of CTRC
and tip the balance toward a disease state.
In the absence of a crystal structure for CTRC, our efforts to
understand this specificity have made use of inhibitor phage
display selection and mutagenesis of the natural substrate cat-
ionic trypsinogen, with somewhat contradictory results (16,
17). Inhibitor studies suggest strong preference for Leu fol-
lowed by Met at the P1 position (17), whereas substrate
mutagenesis suggests that CTRC is much more permissive of
alternative P1 residues (16). Another potential specificity fea-
ture is suggested by the presence of multiple Asp and Glu resi-
dues within favored CTRC target sequences (Table 1); these
acidic residues appear consistently in the P4 position but are
otherwise non-uniformly situated. Inhibitor phage display con-
firms a strong preference for acidic residues at the P4 position
(17), but mutagenesis studies again show only moderate effects
upon alteration of individual charged residues within the cati-
onic trypsinogen Ca2-binding loop (16).
Here, the first structure of activeCTRC reveals a familiar fold
with distinctive electrostatic features surrounding the substrate
binding cleft. The CTRC active site is occupied by the inhibitor
eglin c bound in a substrate-like conformation, offering insights
into the structural basis for the unique substrate specificity of
CTRC toward key physiological and pathological substrate
sequences. Analysis of the structure suggests that whereas the
bulk of binding energy derives from burial of the P1 residue and
several other hydrophobic side chains, specificity may derive
largely from the exaggerated role of long-range electrostatic
interactions, from amoderate preference for Leu at the P1 posi-
tion, and may also be influenced by local sequence-dependent
backbone conformational tendencies.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Human chymotrypsino-
gen C bearing a C-terminal His10 tag was expressed using
transiently transfected HEK 293T cells, purified using metal
chelation chromatography, dialyzed against 50 mM sodium
phosphate (pH 8.0) and 300 mM NaCl, concentrated to 20
mg/ml, and activated by cleavage with cationic trypsin as pre-
viously described (4).
A construct for recombinant bacterial expression of eglin c
from Hirudo medicinalis was a generous gift from Professor
Robert S. Fuller, University ofMichiganMedical School. Eglin c
was expressed in Escherichia coli host strain BL21(DE3) and
purified to homogeneity from periplasmic extract by SP-Sep-
5 Substrate residues surrounding the cleavage site are designated by the
nomenclatureof Schechter andBerger (70): starting from the scissile bond,
substrate residues are numbered P1, P2, P3, etc. in the direction of the N
terminus (collectively the non-primed residues), and P1, P2, P3, etc. in the
direction of the C terminus (collectively the primed residues). Correspond-
ing enzyme subsites are numbered S1, S2, S3, etc.
TABLE 1
Specific substrate/inhibitor sequences recognized by CTRC
The abbreviations used in the table are: Tg1, human cationic trypsinogen; Tg2, human anionic trypsinogen; Tg3, human mesotrypsinogen; proCPA1, human procarboxypep-
tidase A1; proCPA2, human procarboxypeptidase A2; SGPI-2, Schistocerca gregaria proteinase inhibitor-2. *, substrate peptides shaded in gray have been modeled in the
CTRC active site as described in the text, structural coordinates for the models are provided as supplemental Models S1–S3. **, sequence shown is the consensus of multi-
ple clones selected from a phage-displayed SGPI-2 library that was diversified at P4, P2, P1, P1, P2, and P4. Residues shown in parentheses were at positions that were not
diversified in the library.
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harose chromatography essentially as previously described
(18). Eglin c was dialyzed into 10 mM (NH4)2OAc at pH 6.0,
lyophilized, and stored at80 °C until use, when it was recon-
stituted with H2O.
Crystallization—A1:1 (mol/mol)mixture of CTRC and eglin
c was concentrated to achieve a protein concentration of 4–5
mg/ml. Crystallization employed the hanging drop vapor diffu-
sion method. Diffraction quality crystals were grown at room
temperature from droplets containing 0.2 M lithium sulfate
monohydrate, 0.1 M Tris-HCl (pH 8.5), and 30% (w/v) PEG
4000. Crystals grew over the course of 3 weeks to 0.1 0.2
0.2 mm. Crystals were soaked in a cryoprotectant solution
(0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl (pH 8.5),
and 30% (w/v) PEG 4000, and 15% glycerol) and cryocooled
in liquid N2.
Crystals were screened for diffraction and data were col-
lected at 100 K at beamline X29 at the National Synchrotron
Light Source, Brookhaven National Laboratory. The best crys-
tals diffracted to 1.9-Å resolution. We identified crystals of
CTRC/eglin c belonging to orthorhombic space group P212121,
with unit cell dimensions a 56.27, b 76.25, c 81.82, and
containing one complex in the asymmetric unit. The data were
merged and scaled using DENZO/SCALEPACK (19).
Structure Determination—The x-ray structure of chymo-
trypsin C in complex with eglin c was solved by molecular
replacement using Phaser (20) supported by CCP4. The elas-
tase chain from the previously solved structure of a porcine
elastase-inhibitor complex (PDB code 1EAI, chain A) (21) and
eglin c from bovine -chymotrypsin-eglin c (PDB 1ACB, chain
I) (22) were used as search models. ARP/wARP was employed
after molecular replacement for automated rebuilding of the
CTRC-eglin c complex structure (23, 24). A test set of 5% of the
total reflections was excluded from rebuilding and refinement
of the model. Refmac5 (25) was used to carry out refinement
and to place water molecules into difference peaks (Fo  Fc)
greater than 3; manual rebuilding was done using COOT (26).
A 10-residue activation peptide chain that was not liberated
following proteolytic activation of CTRC due to a disulfide link
with the enzyme (chain Q) was manually built into electron
densitymaps (2Fo Fc) using COOT. Phosphate ions were also
added using COOT. The final stage of the restrained refine-
ment included water molecules with peaks greater than 1 and
within acceptable H-bonding distances from neighboring pro-
tein atoms and three phosphate ions. Surprisingly, we were
unable to build either the His10 tag or the N-linked glycosyl
groups of CTRC due to the absence of electron density. The
final R/Rfree was 0.157/0.210. Figs. 1, 2, 4A, and 5 were gener-
ated using PyMOL (Schro¨dinger, LLC).
Homology Modeling of Human Elastase and Chymotrypsin
Isoforms—Homology models of human elastases (ELA2A,
ELA3A, and ELA3B) and chymotrypsins (CTRB1, CTRB2, and
CTRL1) were constructed using the SWISS-MODEL work-
space (27). Homology models were constructed using porcine
elastase bound to an Ascaris chymotrypsin/elastase inhibitor
(PDB code 1EAI, chain A) (21) or our model of active CTRC
bound to eglin c (PDB code 4H4F, chains A andQ) as templates
with 40–50% amino acid identity to the modeled proteins.
Molecular surfaceswere generated using theMolecular Surface
module of Schro¨dinger 2012 (Schro¨dinger, LLC). Molecular
surfaces were based upon high-resolution settings (0.3 Å grid,
probe radius 1.4 Å, and van derWaals radius scale of 1.0 Å). All
surfaces were rendered in red - white - blue color scale using PB
electrostatic potential from calculated charges at pH 8.5 with
the color ramp set to a minimum of 0.35 and maximum of
0.15 for the structures shown in Figs. 3 and 4; the figures were
generated using the Maestro all-purpose molecular modeling
environment, version 9.3.023 from the Schro¨dinger Suite 2012.
Molecular Modeling of CTRC Substrate Binding—The x-ray
structure for CTRC was imported into the Protein-Prepara-
tion-Wizard graphical user interface of Schro¨dinger withMae-
stro 2012 version 9.3.5 (Schro¨dinger, LLC) for adaption to the
OPLS2005 force field. Bond orders were assigned, zero-order
bonds tometalswere determined, disulfide bondswere created,
and all hydrogens were generated for every residue. Hydrogen
bond assignmentwas based on samplingwater orientations and
taking into account crystallographic waters. Protonation states
were predicted for pH 8.5 using PROPKA (28, 29). Steric
clashes were resolved with convergence of a root mean square
deviation to 0.3 Å using the OPLS2005 force field within the
Schro¨dinger interface.
For modeling and molecular docking of peptide substrate
sequences, starting conformations of substrates were obtained
by Polak-Ribiere Conjugate Gradient energyminimization (30)
with the OPLS 2005 force field for 5000 steps, or until the
energy difference between subsequent structures was 0.001
kJ/mol Å (28). Force fieldminimization used a water-based sol-
vent, generating charges with an extended cutoff (van der
Waals 8.0 Å, electrostatic 20 Å, H-bond 4.0 Å). We placed soft
restraints on all residues 6 Å from the modeled substrate by
using harmonic restraints at 100 kcal/mol, and allowed the res-
idues within the 6-Å cutoff to move freely during Polak-Ribiere
Conjugate Gradient energy minimization over 500 iterations
with repetition as necessary to converge upon a gradient
threshold of0.05.
We have previously described themethodology used for sub-
strate docking (31); briefly, the binding site was generated via
overlapping grids based on the x-ray structure with a default
rectangular box centered on the target substrate. Substrates
were docked into the binding site of CTRC using Glide extra
precision (XP) (Glide, version 5.6, Schro¨dinger, LLC); molecu-
lar conformations were sampled using methods described pre-
viously (32). A structure-based pharmacophore score was gen-
erated from the optimized, best scoring pose for each substrate
ligand based on the descriptors from the Glide XP score using
an established approach (31, 33, 34). The energetic value
assigned to each pharmacophore feature was calculated using
Phase (Phase, version 3.2, Schro¨dinger, LLC) as the sum of the
Glide XP contributions of the atoms comprising the site. Over-
all dockings at the active site were quantified and ranked on the
basis of these energetic terms (33, 34). To account for protein
flexibility and lessen the effects of minor steric clashes,
excluded volumes spheres corresponding to 80% of the van der
Waals atomic radii were created for all CTRC atoms within 6 Å
of each substrate ormutagenized residuemodeled. Aminimum
of two poses per substrate, chosen for a combination of best-
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scoring features, was selected for visual and energetic compar-
ison (31, 33, 34).
RESULTS
Structure Solution and Refinement—The structure of active
human CTRC bound to inhibitor eglin c was determined to
1.9-Å resolution in space group P212121 with one bimolecular
complex per asymmetric unit. The structure was solved by
molecular replacement using as search models the previously
reported structures of porcine pancreatic elastase (PDB 1EAI)
(21), featuring 52% sequence identity to human CTRC, and
eglin c (PDB 1ACB) (22). A structure of the bovine CTRC pre-
cursor chymotrypsinogen C, possessing 80% sequence identity
to human CTRC, has been reported previously (PDB 1PYT)
(35); however, the elastase structure was judged to offer a better
search model as a result of substantial conformational changes
that take place upon protease activation (36). The model was
rebuilt and refined to a final Rcryst (Rfree) of 15.7% (21.0%); crys-
tallographic statistics are summarized in Table 2.
Overall Structure of the CTRC-Eglin c Complex—Like other
serine proteases of the chymotrypsin family (37), CTRC is com-
prised of two -barrels, at the interface of which is located the
active site containing the catalytic triad of Ser195 (Ser216),6His57
(His74), and Asp102 (Asp121) (Fig. 1A). The substrate binding
cleft between the-barrels is occupied by bound inhibitor eglin
c, a 70-amino acid protein protease inhibitor originally isolated
from the leech H. medicinalis (38). As has been described pre-
viously for eglin c (22, 39, 40) and for the structurally related
chymotrypsin inhibitor 2 (41, 42), the inhibitor is a wedge-
shaped molecule featuring a hydrophobic core formed by a
helix and a small -sheet, from which protrudes the inhibitory
canonical loop, forming the thin edge of the wedge, which fits
into the substrate binding cleft of the enzyme (Fig. 1, A and B).
The canonical loop of eglin c, comprised of residues 40–50,
binds to the active site of CTRC in the substrate-like fashion
typical of canonical serine protease inhibitors (43–45) (Fig. 1B).
CTRC residues 1–10 of the cleaved activation peptide chain
(CGVPSFPPNL) are retained by the activated enzyme due to a
disulfide link betweenCys1 (Cys17) of the activation peptide and
Cys122 (Cys141), located in the linker between the two -barrels
on the enzyme face distal from the active site (Fig. 1C). The
disulfide bonding pattern and consequent retention of the acti-
vation peptide, conserved among other chymotrypsins and the
elastase 2A isoform, has been demonstrated to stabilize the
enzyme against denaturation and proteolytic digestion by pep-
sin (46). In addition to the covalent link, the activation peptide
association is stabilized by two backbone-backboneH-bonds of
Gly2 (Gly18), an H-bond between the carbonyl of Pro7 (Pro23)
and the side chain of Arg23 (Arg37), and substantial hydropho-
bic interactions of Pro4 (Pro20), Phe6 (Phe22), Pro8 (Pro24), and
Leu10 (Leu26) (Fig. 1C). Clear density is observed for the C-ter-
minal Leu10 (Leu26) of the activation peptide chain, revealing
that residues Ser11-Ala12-Arg15 (Ser27-Ala28-Arg29) of the acti-
vation peptide have been proteolytically removed. Given the
binding preference of CTRC for Leu at the P1 position (17), it is
probable that removal of the tripeptide is accomplished
through autoproteolytic cleavage in trans, as suggested previ-
ously (47).
Although the recombinantCTRCpossessed aHis10 tag, none
of the residues of the tag were visible in the electron density,
suggesting that either the tag was disordered or had been pro-
teolytically removed post-purification by autoproteolysis. Like-
wise, although CTRC has been shown to be glycosylated on
Asn36B (Asn52), amodification required for efficient folding and
secretion (48), we did not observe density for the glycosyl
group. The side chain of Asn36B (Asn52) was poorly defined and
it is likely that the sugar at this site was present but disordered.
Insights into Chymotrypsinogen C Activation—Comparison
of the human CTRC structure with the earlier reported struc-
ture of bovine chymotrypsinogen C (PDB 1PYT) (35) shows
that upon cleavage of the activation loop at Arg15-Val16 (Arg29-
Val30), the new N-terminal residue Val16 (Val30) becomes bur-
ied, forming a salt bridge with Asp194 (Asp215) and an H-bond
with the carbonyl oxygen of Arg143 (Arg162). This reorganiza-
tion has little impact on the structure of the first -barrel
domain, but results in major conformational alterations of the
second -barrel domain, particularly within loops 1 and 2,
which shape the S1 specificity pocket and oxyanion hole, and
loopD,which helps to shape the primed side subsites. Although
the catalytic triad residues are already roughly positioned in
chymotrypsinogen C, small conformational adjustments in all
three members of the triad bring them into appropriate align-
ment for catalysis, reducing the Ser195 O-His57 N2 distance
from 3.83 to 2.88 Å, and shortening the His57 N1-Asp102 O2
H-bond from 2.95 to 2.55 Å. These alterations are typical of the
conserved mechanism of activation of chymotrypsinogen fam-
ily members (13).
Details of the Inhibitory Interaction—The inhibitory loop of
eglin c is stabilized in the distinctive canonical conformation by
6 The CTRC residue numbering used in this report and in the crystal structure
coordinates is derived by homology to bovine chymotrypsin, the arche-
typal member of this peptidase family, for consistency with structural lit-
erature in the serine protease field. Designations in parentheses are the
corresponding residue numbers based on sequential numbering of the
CTRC precursor.
TABLE 2
Crystallographic data collection and refinement statistics for CTRC-
eglin c complex
PDB ID 4H4F
Complexes per ASU 1
Space group P212121
Unit cell, Å 56.27, 76.25, 81.82
90°, 90°, 90°
Resolution, Å 1.9
Unique reflections 27,661
Completeness (%) 97.34 (76.8)a
Multiplicity 6.8 (4.8)a
Mean I/ () 51.3 (9.0)a
R-merge 0.043 (0.146)a
Rsym 0.043 (0.146)a
Rcryst/Rfree (%) 0.157/0.210
Root mean square deviation bonds, Å 0.027
Root mean square deviation angles (degree) 2.066
Protein atoms 2469
Ions 3 (PO42)
Water molecules 320
	,
 angle distributionb
In favored regions 209 (87.8%)
In additionally allowed regions 28 (11.8%)
In generously allowed regions 1 (0.4%)
a Values in parentheses are for the highest resolution shell (1.93–1.9 Å).
b Ramachandran distribution is reported as defined by PROCHECK/PDB
validation.
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a hydrophobic “mini-core” (49) comprised of Leu37, Val43, and
Phe55, and by a H-bond network involving Thr44, Asp46, the
Arg48 backbone N, Arg51, Arg53, and the C-terminal carboxyl
group of Gly70 (Fig. 2A). This H-bond network is critical for
maintaining protease affinity and resistance to proteolysis of
the inhibitor (50–54).
The mode of protease binding of canonical inhibitors like
eglin c has been shown to very closely mimic the reactive
Michaelis complex with a true peptide substrate (45). As is typ-
ical of such complexes, the Leu45-Asp46 reactive site peptide
bond of eglin c is appropriately positioned for nucleophilic
attack by the catalytic Ser195 (Ser216) of CTRC (Fig. 2B), the
initial step in enzyme-catalyzed proteolysis. The largely hydro-
phobic substrate binding cleft of CTRC is fully occupied by
eglin c residues 40–50, whichmimic non-primed side substrate
residues P1-P6 and primed side residues P1-P5. The non-
primed side residues are positioned by antiparallel backbone-
backbone H-bonds between the P3 residue Val43 and CTRC
Gly216 (Gly238), and between the P1 residue Leu45 and CTRC
Ser214 (Ser236) (Fig. 2C). The Leu45 carbonyl oxygen is posi-
tioned to interact with the CTRC oxyanion hole amide nitro-
gens of Ser195 (Ser216) and Gly193 (Gly214). On the primed side,
additional H-bonds are formed between P2 residue Leu47 and
CTRC Thr41 (Thr58) (Fig. 2C).
The S1 primary specificity pocket of CTRC, occupied in the
complex by the side chain of eglin c Leu45, is shaped by the
hydrophobic side chains of CTRC residues Ala190 (Ala211),
Val213 (Val235), and Val226 (Val250) (Fig. 2C). A more shallow
hydrophobic depression in the substrate binding cleft is shaped
by the side chains of CTRC Leu99 (Leu118) and Phe215 (Phe237),
which form a binding pocket for P4 residue Pro42. On the
primed side, the S2 subsite, a pocket bordered by the basic side
chain of CTRCArg143 (Arg162) and the hydrophobic side chain
of Ile151 (Ile169), is filled by the hydrophobic P2 residue Leu47
(Fig. 2C).
The backbone conformation of eglin c residues 43–49 bound
to CTRC closely parallels that seen in the previously reported
structure of eglin c with bovine -chymotrypsin (PDB 1ACB
(22)). By contrast, eglin c residues 39–42 are shifted compared
with the bovine -chymotrypsin-eglin c complex to lie 3 Å
further removed from a basic patch formed by CTRC residues
Arg175 (Arg195), Arg218 (Arg241), and Lys224 (Lys248) (Fig. 2D).
This basic pocket forms the S6 subsite of CTRC, which is occu-
pied in the complex by a coordinated phosphate ion in the
absence of a side chain on the eglin c P6 residue Gly40 (Fig. 2D).
Structural Insights into CTRC Substrate Specificity—CTRC
has been shown to act as a regulator of pancreatic zymogen
activation by targeting a specific set of substrate cleavage sites
not recognized by other chymotrypsin or elastase-like digestive
proteases (Table 1) (5, 6, 15, 16). One element of this specificity
is more highly efficient cleavage after Leu residues when com-
pared with other chymotrypsin and elastase isoforms (16). By
contrast, the elastase isoforms show broad P1 specificity but
comparatively low catalytic efficiency on short peptide sub-
strates, whereas chymotrypsins prefer aromatic residues Phe,
Tyr, or Trp at P1 (16). The position occupied in CTRCbyVal226
(Val250), one of the hydrophobic residues shaping the S1 pocket
(Fig. 2C), is in other chymotrypsins filled by Gly or Ala, and the
FIGURE 1.Crystal structure of the CTRC-eglin c complex.A, structural over-
view of the complex. CTRC is shown in blue, with catalytic triad residues
Ser195, His57, and Asp102 in red and disulfide links in yellow. Eglin c is displayed
in green. B, view into the substrate binding cleft of CTRC. CTRC is shown with
a semitransparent gray surface. Eglin c binding loop residues 40–50 are ren-
dered in stick representation, filling (from left to right) CTRC S6-S1 and S1-S5
subsites. C, retained activation peptide of CTRC. Residues 1–10 of the chymo-
trypsin C activation peptide are tethered to the activated enzyme through a
disulfide link between Cys1 and Cys122. The activation peptide is depicted in
cyan in stick representation, with a 2Fo Fc electron density map contoured
at 1.6. Strong density around the Leu10 carboxyl terminus confirms that
residues 11–13 of the activation peptide are not disordered but have been
proteolytically removed.
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bulkier Val residue at this position is likely to be responsible for
themodest binding selectivity of CTRC for Leu in preference to
Met, Phe, or Tyr at the P1 position, as identified by phage dis-
play selection and inhibitor binding studies (17) and by Km val-
ues for cleavage of tetrapeptide substrates (16). Nevertheless,
the S1 subsite of CTRC is still capable of accommodating aro-
matic residues, and in fact, CTRC catalytic rates are slightly
enhanced for cleavage after these bulkier residues, resulting in
comparable catalytic efficiencies for cleavage after Leu, Met,
Phe, or Tyr (16). This result is also consistent with the identifi-
cation of natural CTRC cleavage sites within protein substrates
after Phe, Leu, and Tyr (Table 1).
Another distinctive feature shared by the natural target sites
of CTRC is an unusual clustering of acidic residues. Asp or Glu
appear very frequently at the P4 position, an element of speci-
ficity corroborated by phage display selection (17). Acidic resi-
dues can also be found at P1, P2, P3, and P5 on the primed
side of the cleavage site, and at P3, P5, and P6 on the non-primed
side of the cleavage site (Table 1). To gain insight into the prob-
able electrostatic contribution to this unusual substrate speci-
ficity, we calculated the predicted electrostatic surface potential
of the CTRC structure, and for comparison we generated
homology models and calculated electrostatic surfaces for
other human chymotrypsin and elastase isoforms, which do not
target the same regulatory cleavage sites (Fig. 3).We observed a
particularly striking concentration of positive charge in a ring
surrounding the substrate binding cleft of CTRC (Fig. 3, top).
The most intense concentrations of positive charge are created
by one cluster of basic residues on the non-primed side of the
cleft in the region that makes contact with P5 and P6 substrate
residues, and a second cluster of basic residues on the primed
side bordering the subsites that recognize P2, P3, and P4 sub-
strate residues. Notably, this charge distribution contrasts
markedly with the predicted electrostatic surfaces of other ela-
stase and chymotrypsin isoforms (Fig. 3, lower panels). The
human elastases feature small patches of both positive and neg-
ative charge in roughly equal proportions, whereas human chy-
motrypsins possess substrate binding clefts linedwith primarily
negative charge. Thus, the unusual concentration of positive
charge surrounding theCTRCsubstrate binding cleft is likely to
be a major determinant driving specificity for substrate
sequences of net negative charge.
Modeling of CTRC-Substrate Complexes—Selection by CTRC
among several potential cleavage sites within human cationic
trypsinogen has profound health implications. Whereas cleav-
age in the trypsinogen Ca2-binding loop is a normal mecha-
nism for CTRC to apply the brakes to a premature cascade of
digestive enzyme activation in the pancreas (6), an alternative
cleavage within the activation peptide has the potential to
accelerate this activation cascade (5). To serve its protective
function, CTRC must significantly favor the former cleavage
over the latter in the pancreas environment. To gain insight
into the interactions of competing cleavage sites with CTRC,
we examined the structural context of the Ca2-binding loop
FIGURE2.Eglin c inhibitory interactionwithCTRC.A, stabilizationof the inhibitory loopof eglin c. Theeglin cbinding loopassumes a substrate-like canonical
conformation of the peptide backbone, stabilized on the nonprimed side by hydrophobic interactions of Leu37, Val43, and Phe55, and on the primed side by an
H-bond network involving Thr44, Asp46, the Arg48 amide nitrogen, Arg51, Arg53, and C-terminal Gly70. The side chain of Arg48 is omitted for clarity. B, the
CTRC-eglin c complex resembles an enzyme-substrateMichaelis complex. The Leu45-Asp46 reactive site peptide bondof eglin c, linking the P1 andP1 residues,
lies in proper orientation for attack by the catalytic Ser195 of CTRC. The 2Fo Fc electron density map is shown contoured at 2.0. C, key CTRC-eglin c binding
interactions. The eglin c P1 residue Leu
45 fills the S1 pocket bordered by CTRCAla
190, Val213, and Val226. P4 residue Pro
42 fills a hydrophobic concavity formedby
CTRC Leu99 and Phe215. P2 residue Leu
47 fills a pocket formed by CTRC Arg143 and Ile151. Multiple backbone H-bonds orient the inhibitor, indicated by black
dotted lines. D, positively charged P6 pocket displaces eglin c backbone to bind phosphate. Basic side chains of CTRC Arg
175, Arg218, and Lys224 coordinate a
phosphate ion, displacing eglin c from the orientation in which it is found in complex with bovine -chymotrypsin (shown in semitransparent white stick
representation; PDB code 1ACB). The 2Fo Fc electron density map shown for the phosphate ion is contoured at 1.6.
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site in our previously reported structure of human cationic
trypsin (55), and we also used the new CTRC structure as a
starting point to generate models of CTRC bound to specific
substrate sequences.
In the cationic trypsin structure, Ca2 is coordinated within
the loop by the side chains of residues Glu75 and Glu85, which
anchor the base of the loop, and by carbonyl oxygens of Asn77
and Val80 (Fig. 4A).7 CTRC targets the Leu81-Glu82 peptide
bond for cleavage. With Ca2 bound, Leu81 is exposed and
accessible to CTRC; however, the peptide backbone stretching
away from the cleavage site is unable to assume the canonical
conformation required for cleavage (56). Cationic trypsinogen
possesses a large number of acidic residues in this region; in
7 The human cationic trypsinogen residue numbering used here is based on
sequential numbering of the trypsinogen precursor as is conventionally
used in designating natural polymorphisms, e.g. p.A16V.
FIGURE 3.Distinct highly charged electrostatic surface of CTRC. The elec-
trostatic surface potential of CTRC (top) shows intense concentration of a
positive charge (blue) surrounding the active site cleft. Positions of substrate-
binding subsites are indicated by black arrows. Smaller panels below show for
comparison the electrostatic surface potentials generated for homology
models of human elastase isoforms (left) and chymotrypsin isoforms (right).
Molecular surfaces were generated using the Molecular Surface module of
Schrodinger 2012asdescribedunder “Experimental Procedures”; the electro-
static potential color ramp was set from a minimum of0.35 to a maximum
of 0.15.
FIGURE 4. Cationic trypsinogen Ca2-binding loop targeted for cleavage
by CTRC. A, the Ca2-binding loop of human cationic trypsinogen contains
multiple acidic residues (orange), with additional acidic residues located in
nearby neighboring loops. The bound Ca2 is shown in purple; the Leu81-
Glu82 peptide bond represents the preferred cleavage site targeted by CTRC.
Structure coordinates are from PDB code 2RA3 (55). B, the electrostatic sur-
face potential calculated for cationic trypsin reveals a negative charge sur-
rounding the site of bound Ca2, indicated by the large black arrow. Molecu-
lar surfaces were generated using the Molecular Surface module of
Schrodinger 2012asdescribedunder “Experimental Procedures”; the electro-
static potential color ramp was set from a minimum of0.35 to a maximum
of 0.15. C, Ca2-binding loop cleavage sequence of cationic trypsinogen is
shown modeled into the active site cleft of CTRC. The hydrophobic side
chains of Ile78 and Leu81 occupy the complementary S4 and S1 subsites,
respectively. Acidic residues are shown in orange; Glu79 at the P2 position and
Glu85 at the P4 position are near CTRC regions of positive surface potential.
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addition to Glu75 and Glu85, there are two additional glutama-
tes in the loop (Glu79 andGlu82), as well as three acidic residues
in neighboring loops (Glu32, Asp156, and Glu157; Fig. 4A). Thus,
even with Ca2 present to neutralize the charge of Glu75 and
Glu85, there is a strongly negative electrostatic potential cover-
ing this region of the molecule (Fig. 4B). This potential will
generate macroscopic electrostatic complementarity between
the Ca2-binding loop of cationic trypsin or trypsinogen and
the substrate-binding site of CTRC. It is anticipated that when
Ca2 is released, this loop becomesmore flexible and accessible
to CTRC, able to assume a productive binding orientation, and
that electrostatic attraction may increase further due to expo-
sure of Glu75 and Glu85.
Because eglin c binds toCTRC in the canonical orientation of
an ideal substrate (45), we were able to model substrate
sequences into the binding cleft of CTRC using eglin c as a
template and then to optimize the interactions through energy
minimization. Models were generated for CTRC bound to the
human cationic trypsinogen activation peptide (APFDDDDK)
and the CTRC-labile site within the cationic trypsinogen Ca2-
binding loop (HNIEVLEGNEQ). The resulting “global” total
enthalpies (H) from energy minimization were70,572 and
71,057 kcal/mol, respectively. Following modeling and
minimization, we conducted substrate docking for each sub-
strate with CTRC, giving docking scores of 10.16 and
17.72 kcal/mol, respectively. The cationic trypsinogen
Ca2-binding loop, which contacts the greater number of
non-primed side subsites, was predicted to be the more pre-
ferred substrate based on overall lowest energy from dock-
ing/binding with CTRC.
The docked model of preferred substrate HNIEVLEGNEQ
shows the positioning of substrate residues relative to the elec-
trostatic features of theCTRC surface (Fig. 4C); residuesAsn77-
Ile78-Glu79-Val80-Leu81-Glu82-Gly83-Asn84-Glu85 fill the
largely hydrophobic cleft between the flanking clusters of pos-
itive charge, with the Leu81 side chain embedded in the hydro-
phobic S1 subsite. Surprisingly, none of the acidic side chains of
the substrate, Glu79, Glu82, or Glu85, which fill the P3, P1, and
P4 positions, respectively, form direct salt bridges with the
clustered basic side chains of CTRC in the energy minimized
docked model (Fig. 5A). Instead, it would appear that the com-
plex stabilization attributable to charge complementarity
derives from longer range electrostatic interactions. Trypsino-
genGlu82 in the P1position is stabilized byCTRCArg62A via an
interaction bridged by H-bonds with the P3 side chain of tryp-
sinogen Asn84. The trypsinogen Glu85 P4 side chain is posi-
tioned equidistant from the guanidinium groups of CTRC
Arg39 and Arg143 (about 6 Å from each). The major favorable
close interactions in the complex are comprised primarily of
hydrophobic and van der Waals interactions, and a series of
hydrogen bonds tethering the substrate peptide backbone
within the binding cleft (Fig. 5A).
The docked model of the competing substrate cleavage site,
APFDDDDK (the trypsinogen activation peptide), shows that
this shorter substrate fills only the S1-S3 subsites on the non-
primed side of the cleft, forming fewer H-bonds and hydropho-
bic interactions as comparedwith the longer substrate (Fig. 5B).
In this model, Phe18 fills the hydrophobic S1 subsite, and the
substrate does form a single direct salt bridge between Asp20 at
the P2 position and Arg143 (Arg162) of CTRC (Fig. 5B). How-
ever, as was the case for the Ca2-binding loop site, electro-
static stabilization conferred by the Asp residues at the P1, P3,
and P4 positions is apparently mediated through longer-range
interactions with CTRC.
Mutation of a single residue in the trypsinogen activation
peptide, where Val is substituted for Ala16 at the P3 position,
predisposes carriers for development of pancreatitis, appar-
ently by altering the balance of the CTRC substrate selectivity
in favor of the activation peptide (4, 7, 8). To explore the struc-
tural basis for this shift in selectivity, we modeled the complex
of CTRCwith the p.A16Vmutant sequence. The dockedmodel
of the p.A16V mutant trypsinogen activation peptide VPFD-
FIGURE 5. Structural modeling of CTRC-substrate interactions. A, trypsin-
ogen Ca2-binding loop substrate positioning relative to nearby CTRC resi-
dues illustrates H-bonds formedbetween enzyme and substrate as black dot-
ted lines. None of substrate acidic residues Glu79, Glu82, or Glu85 lie in close
enough proximity to the CTRC basic side chains to form direct salt bridges. B,
a similar view showing a model of trypsinogen activation peptide cleavage
sequence bound to CTRC. This shorter alternative substrate forms one fewer
non-primed side hydrogen bond with the enzyme, and lacks the hydropho-
bic stabilization thatwould be provided by a P4 substrate residue. However, a
direct salt bridge is formedbetweenP2 residueAsp
20 andCTRCArg143.C and
D, minimal differences are present in models of trypsinogen activation pep-
tide (C) and p.A16V mutant (D) bound to CTRC. Where the Ala16 N-terminal
amine is predicted to hydrogen bondwith the CTRCGly216 carbonyl (C), rota-
tion of the Val16 (magenta) eliminates this bond but the bulkier side chain
forms additional hydrophobic contacts with the Pro17 ring and the -carbon
of Arg217A (D).
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DDDK very closely resembles that of the wild-type sequence,
with significant differences confined to the mutated residue
itself. The N-terminal amine of Ala16 H-bonds to the CTRC
Gly216 carbonyl in the model of the wild-type sequence (Fig.
5C), whereas in the mutant model this H-bond is disrupted by
slight rotation of Val16 to optimize hydrophobic contacts with
the Pro17 ring and with the -carbon of Arg217A (Fig. 5D). The
impact of the mutation on binding interactions with CTRC
suggested by these models would not appear to be sufficient to
explain the functional importance of the mutation in predis-
posing carriers to pancreatitis.
Consistentwith theseminimal structural differences, the cal-
culated binding energy for the p.A16V mutant sequence was
very close to that of the wild-type sequence (8.811 versus
10.16 kcal/mol, respectively) and did not suggest enhanced
binding upon mutation as might be predicted by functional
studies (4, 5). One possible explanation for this apparent dis-
crepancy is that the energy calculations do not take into
account entropic components of binding energy, which may
differ between the substrate sequences. This explanation is
highly plausible, because entropic factors involved in binding
are anticipated to differ between thewild-type andmutant acti-
vation peptides as detailed further under “Discussion.” Thus, it
is probable that the mutation critically influences the confor-
mational ensemble and dynamics of the activation peptide in its
unbound form, resulting in differential entropic contributions
to formation of theCTRC-substrate complex and thereby alter-
ing cleavage selectivity.
DISCUSSION
On one hand, biochemical studies with purified proteins
show that CTRC, like most digestive proteases, is capable of
proteolytic cleavage of multiple target sequences revealing no
highly conserved recognitionmotif (Table 1). CTRC appears to
be relatively insensitive to a variety of mutations of the trypsin-
ogen Ca2-binding loop cleavage site (16), further suggesting
fairly promiscuous activity. On the other hand, incontro-
vertible genetic evidence demonstrates that a subtle muta-
tion of the CTRC cleavage site within the cationic trypsino-
gen activation peptide predisposes to development of
chronic pancreatitis (7, 8), as does loss of function of CTRC
itself (9–12); these observations reveal a specific regulatory
role for the enzyme.
To reconcile these contrasting views of CTRC specificity, we
consider how the protease selects its substrates in vivo. Steady
state enzyme kinetics studies using individual substrates can
reveal the thermodynamic stability of the Michaelis complex
(Km) and the overall catalytic rate of the reaction (kcat) from
which the specificity constant kcat/Km is derived. However, in
the scenario in which multiple candidate substrates are in
direct competition, kinetic rather than thermodynamic control
may prevail (57, 58). Protein-protein association is a multistep
process, with differentmolecular forces influencing the rates of
each step, and electrostatic interactions provide the dominant
long-range force capable of accelerating the rate of initial
molecular collision (58, 59). The intense concentration of pos-
itive charge surrounding the CTRC active site, yet apparently
not positioned for optimal formation of tight salt bridges in the
final Michaelis complex, suggests that this funnel-like ring of
surface chargemay instead be optimized to kinetically favor the
initial attraction of polyacidic substrate sequences, akin to a
molecular tractor beam.
Nonspecific long-range electrostatic attraction will be a
dominant driving force as CTRC and its substrate first
approach each other, at a stage when they may not yet be cor-
rectly rotationally oriented. The stabilization conferred by elec-
trostatic attraction, combined with the viscosity of the sur-
rounding solution, may also extend the lifespan of the low
affinity transient complex, allowing the two proteins to rotate
and sample multiple trajectories of approach in repeated
microcollisions (58). Thus, an electrostatically complementary
substratewill have enhanced probability of finding a productive
binding conformation, achieving the Michaelis complex, and
becoming proteolyzed. A similar influence of electrostatic
potential on substrate specificity was observed previously for
the hepatitis C virus NS3 protease using pre-steady state kinet-
ics, where clusters of positively charged residues near the active
site, complementary to clusters of negative charge on the sub-
strate, were found to drive very rapid association (60). The
influence of these long-range interactions on substrate selec-
tion in vivo may be underestimated in comparisons of overall
substrate affinity, which depend upon the relative rates of for-
mation and dissociation of the high affinityMichaelis complex.
The later stages of binding thatmark the progression from tran-
sient to Michaelis complex are likely to be slower, due to the
radical alterations of local substrate conformation often
required (56).
Following formation of a roughly aligned encounter com-
plex, the next stage of CTRC-substrate association is likely to be
docking of the large hydrophobic P1 “anchor” residue within
the S1 subsite (57). As with electrostatic charge, the kinetic
importance of this interaction and its impact on specificity
under conditions of direct substrate competitionmaybe under-
estimated in studies with single purified substrates. For exam-
ple, CTRC binding studies with tight binding inhibitors
revealed a clear preference for P1 Leu over Met, both of which
were representedmuchmore highly thanPhe orTyr in a pool of
inhibitors selected by phage display (17). By contrast, CTRC
appeared insensitive to mutation of the P1 Leu in the tryp-
sinogen Ca2-binding loop to Met, Tyr, or Phe (16). We
would speculate that in the case of the rigidly structured
inhibitors, the overall rate of association reflects the rate of
P1-S1 docking, which is fastest for Leu due to optimal com-
plementarity with the S1 pocket. By contrast, with highly
flexible or natively unstructured substrate sequences, the
slower rate with which flanking residues conform to adjacent
subsites through induced fit (57) may mask the importance
of P1 specificity.
CTRC serves a protective function in the pancreas, as dem-
onstrated by the association of CTRC loss of function with
chronic pancreatitis (9–12), and by the finding that pathologi-
cal activation of hereditary pancreatitis-causing cationic tryp-
sinogen mutants is dependent on CTRC activity (4). We have
found that CTRC can cleave cationic trypsinogen at alternative
cleavage sites; proteolysis within the trypsinogen activation
peptide leads to enhanced autoactivation of trypsin (5), whereas
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proteolysis within the Ca2-binding loop leads to trypsinogen
degradation (6). The protective function of CTRC would sug-
gest that the dominant activity of CTRC activated in the pan-
creas must be the degradation of cationic trypsinogen, initiated
by cleavage within the Ca2-binding loop.
Our modeling results are consistent with the idea that when
sterically accessible, the Ca2-binding loop is the more pre-
ferred site of cleavage. This site fills a greater number of
nonprimed subsites, burying a greater solvent accessible sur-
face area, it possesses the preferred Leu at the anchor P1 posi-
tion, and it is calculated to have a thermodynamically more
favorable binding energy. In the absence of bound Ca2, the
Ca2-binding loop may be preferred by CTRC from the
perspective of long-range electrostatic interactions as well,
because it possesses four Glu residues within the primary
sequence of the loop and an additional three exposed acidic
residues on nearby loops. In comparison, the unstructured acti-
vation peptide possesses four tandemAsp residues, but the neg-
ative charge of these side chains would be offset by an adjacent
Lys residue and by the N-terminal amine.
It is more difficult to explain from a structural perspective
why the p.A16V mutant trypsinogen activation peptide is
improved as a CTRC substrate, to the extent of significantly
diminishing the protective function of CTRC in the pancreas.
However, it may be as a result of the impact of this substitution
on the conformational ensemble represented by the activation
peptide and on its dynamics. The activation peptide is at the N
terminus of trypsinogen, and is unstructured in the crystal
structures of bovine and rat trypsinogens (61–63). In this
unstructured state, the Ala16-Pro17 (or Val16-Pro17) peptide
bond exists as an equilibrium mixture of cis and trans isomers
(64, 65), and the bulkier Val16 will greatly reduce the rate of
cis-trans isomerization (66). Perhaps more importantly, the
steric bulk of the proline ring restricts the conformations avail-
able to the preceding residue (67), and the -branched Val16
will encounter further restrictions than the smaller Ala16 (68).
To bind to the CTRC active site and undergo proteolysis, the
Pro peptide bond must assume the trans configuration (69),
and both residues must conform to the idealized binding mode
of a canonical loop, inwhich theP3 residuemain chain assumes an
antiparallel -strand conformation and the P2 residuemain chain
assumes a polyproline II conformation (43).We speculate that the
steric restrictions and reduced mobility of the p.A16V mutant
have the effect of locking the activation peptide into a more sub-
strate-like conformation, or of biasing the conformational
ensemble toward a more substrate-like conformation. The
impact would be to minimize the unfavorable entropic con-
tribution to the binding energy, rendering the p.A16V
mutant trypsinogen activation peptide a more favorable
substrate.
In conclusion, themolecular structure and analyses of CTRC
presented here offer mechanistic insight into the striking selec-
tivity of the enzyme for regulatory sites in trypsinogens and
procarboxypeptidases. Long-range electrostatic interactions
between enzyme and substrate, rather than specific charge
pairing, underlie substrate discrimination. In addition, the
structure of CTRC establishes a framework that may enable
interpretation of the functional effects of other clinically signif-
icant trypsinogenmutations that impact CTRC substrate selec-
tivity, as well as mutations within CTRC itself that modify risk
for development of chronic pancreatitis.
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